Kumar Venkata V Pavan, Srinivas Nuggehally R
Integrated Drug Development, Suramus Biopharm, J.P. Nagar I Phase, Bangalore 560078, India.
Eur J Drug Metab Pharmacokinet. 2008 Oct-Dec;33(4):247-52. doi: 10.1007/BF03190880.
Allometric principles have been applied to scale and predict human pharmacokinetic parameters of irbesartan, an important AT1 receptor antagonist. The preclinical data gathered from rats, macaques (monkeys) and dogs were used in the allometric analysis. The use of these species was rationalized because preclinical models based on these species have been used in the evaluation pharmacodynamic activity of irbesartan. The human parameter values for clearance (CL/F), volume of distribution (V/F), and elimination rate constant (Kel) were scaled using simple allometry (CL/F, V/F and Kel) or with correction factors (CL/F). The predictions of both CL/F and elimination half life (T1/2) (using Kel) for irbesartan appeared to be in close proximity to the respective human reported values (CL/F: predicted=18 L/h, observed=22.2 L/h; T1/2: predicted = 9 h; observed = 10-20 h); while, V/F value was marginally over predicted by 1.75-fold using simple allometry (predicted = 456 L; observed = 260 L). The present work presents an opportunity for prospective allometric scaling for the compounds belonging to this important therapeutic class.
异速生长原理已被应用于估算和预测重要的AT1受体拮抗剂厄贝沙坦的人体药代动力学参数。在异速生长分析中使用了从大鼠、猕猴(猴子)和狗收集的临床前数据。使用这些物种是合理的,因为基于这些物种的临床前模型已用于评估厄贝沙坦的药效学活性。通过简单的异速生长法(CL/F、V/F和Kel)或使用校正因子(CL/F)对清除率(CL/F)、分布容积(V/F)和消除速率常数(Kel)的人体参数值进行了估算。厄贝沙坦的CL/F和消除半衰期(T1/2)(使用Kel)预测值似乎与各自报道的人体值非常接近(CL/F:预测值 = 18 L/h,观察值 = 22.2 L/h;T1/2:预测值 = 9 h;观察值 = 10 - 20 h);而使用简单异速生长法时,V/F值略微高估了1.75倍(预测值 = 456 L;观察值 = 260 L)。本研究为属于这一重要治疗类别的化合物进行前瞻性异速生长缩放提供了机会。